The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) is an appointed, pan-Canadian advisory body to CADTH composed of individuals with expertise in cancer drug therapy, drug evaluation and drug utilization, and patient members (for a lay perspective).
As part of the CADTH reimbursement review process, pERC makes reimbursement recommendations for oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug programs. It also makes recommendations related to the identification, evaluation, and promotion of optimal drug prescribing and use in Canada.
pERC's approach is evidence based, and the advice reflects medical and scientific knowledge, current clinical practice, economics, ethical considerations, and patient and public impact.
pERC is appointed by, and reports to, CADTH's President and CEO. Members must abide by the Conflict of Interest Guidelines for CADTH Expert Committee and Panel Members and the CADTH Code of Conduct. An honorarium is paid to pERC members for their preparation and meeting time.
To ensure the consistency and transparency of its cancer drug review process, pERC follows a well-defined deliberative framework. This framework describes all the elements that should be considered by pERC during its review.
Each element is important to the review, and it is the sum consideration of all elements that pERC uses to formulate a funding recommendation.
All pERC members have experience with and a good understanding of issues related to cancer diagnosis, treatment, and care. Each member must also comply with CADTH's conflict of interest, confidentiality requirements, and code of conduct. Professional members of pERC are drawn from the fields of medicine, pharmacy, pharmacology, or health economics. Patient members are selected because of their personal knowledge of, experience with, and understanding of issues related to cancer and its management, among other qualifications. pERC has up to 17 voting members including the three patient members.